PBYI Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 32.68% compared to Puma Biotechnology's net margin of 15.24%. Puma Biotechnology's return on equity of 47.89% beat Johnson & Johnson's return on equity of 19.98%.

Puma Biotechnology has a consensus price target of $4.33, signalling upside risk potential of 30.52%. On the other hand Johnson & Johnson has an analysts' consensus of $169.07 which suggests that it could grow by 3.84%. Given that Puma Biotechnology has higher upside potential than Johnson & Johnson, analysts believe Puma Biotechnology is more attractive than Johnson & Johnson.

Puma Biotechnology has a beta of 1.334, which suggesting that the stock is 33.42% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.473, suggesting its less volatile than the S&P 500 by 52.686%.

Puma Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.05% to investors and pays a quarterly dividend of $1.24 per share. Puma Biotechnology pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Puma Biotechnology quarterly revenues are $59.1M, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Puma Biotechnology's net income of $19.3M is lower than Johnson & Johnson's net income of $3.4B. Notably, Puma Biotechnology's price-to-earnings ratio is 5.44x while Johnson & Johnson's PE ratio is 28.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology is 0.70x versus 4.45x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Pro-Dex has a net margin of 32.68% compared to Puma Biotechnology's net margin of 12.15%. Puma Biotechnology's return on equity of 47.89% beat Pro-Dex's return on equity of 21.59%.

Puma Biotechnology has a consensus price target of $4.33, signalling upside risk potential of 30.52%. On the other hand Pro-Dex has an analysts' consensus of $54.00 which suggests that it could grow by 8.74%. Given that Puma Biotechnology has higher upside potential than Pro-Dex, analysts believe Puma Biotechnology is more attractive than Pro-Dex.

Puma Biotechnology has a beta of 1.334, which suggesting that the stock is 33.42% more volatile than S&P 500. In comparison Pro-Dex has a beta of 0.682, suggesting its less volatile than the S&P 500 by 31.755%.

Puma Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pro-Dex offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Puma Biotechnology pays -- of its earnings as a dividend. Pro-Dex pays out -- of its earnings as a dividend.

Puma Biotechnology quarterly revenues are $59.1M, which are larger than Pro-Dex quarterly revenues of $16.8M. Puma Biotechnology's net income of $19.3M is higher than Pro-Dex's net income of $2M. Notably, Puma Biotechnology's price-to-earnings ratio is 5.44x while Pro-Dex's PE ratio is 24.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology is 0.70x versus 2.77x for Pro-Dex. Usually stocks with elevated PS ratios are considered overvalued.

Spero Therapeutics has a net margin of 32.68% compared to Puma Biotechnology's net margin of -219.3%. Puma Biotechnology's return on equity of 47.89% beat Spero Therapeutics's return on equity of 4.36%.

Puma Biotechnology has a consensus price target of $4.33, signalling upside risk potential of 30.52%. On the other hand Spero Therapeutics has an analysts' consensus of $5.00 which suggests that it could grow by 539.06%. Given that Spero Therapeutics has higher upside potential than Puma Biotechnology, analysts believe Spero Therapeutics is more attractive than Puma Biotechnology.

Puma Biotechnology has a beta of 1.334, which suggesting that the stock is 33.42% more volatile than S&P 500. In comparison Spero Therapeutics has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.497%.

Puma Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Puma Biotechnology pays -- of its earnings as a dividend. Spero Therapeutics pays out -- of its earnings as a dividend.

Puma Biotechnology quarterly revenues are $59.1M, which are larger than Spero Therapeutics quarterly revenues of $7.8M. Puma Biotechnology's net income of $19.3M is higher than Spero Therapeutics's net income of -$17.1M. Notably, Puma Biotechnology's price-to-earnings ratio is 5.44x while Spero Therapeutics's PE ratio is 9.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology is 0.70x versus 0.47x for Spero Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals has a net margin of 32.68% compared to Puma Biotechnology's net margin of -9.24%. Puma Biotechnology's return on equity of 47.89% beat Vanda Pharmaceuticals's return on equity of -3.49%.

Puma Biotechnology has a consensus price target of $4.33, signalling upside risk potential of 30.52%. On the other hand Vanda Pharmaceuticals has an analysts' consensus of $12.67 which suggests that it could grow by 154.35%. Given that Vanda Pharmaceuticals has higher upside potential than Puma Biotechnology, analysts believe Vanda Pharmaceuticals is more attractive than Puma Biotechnology.

Puma Biotechnology has a beta of 1.334, which suggesting that the stock is 33.42% more volatile than S&P 500. In comparison Vanda Pharmaceuticals has a beta of 0.689, suggesting its less volatile than the S&P 500 by 31.079%.

Puma Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Puma Biotechnology pays -- of its earnings as a dividend. Vanda Pharmaceuticals pays out -- of its earnings as a dividend.

Puma Biotechnology quarterly revenues are $59.1M, which are larger than Vanda Pharmaceuticals quarterly revenues of $53.2M. Puma Biotechnology's net income of $19.3M is higher than Vanda Pharmaceuticals's net income of -$4.9M. Notably, Puma Biotechnology's price-to-earnings ratio is 5.44x while Vanda Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology is 0.70x versus 1.46x for Vanda Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.